Patrick Daly

DocwireNews

In adult patients with aplastic anemia, hematopoietic stem cell transplantation (HSCT) from a related haploidentical donor source plus post-transplantation cyclophosphamide (PTCy) for graft-versus-host disease (GHVD) prevention “achieved significantly higher neutrophil and platelet engraftment rates” compared with umbilical cord blood transplantation (UCBT), according to a retrospective analysis in Transplantation and Cellular Therapy.
The researchers, led by Yasushi Onishi, MD, of Tohoku University Hospital in Japan, noted that allogeneic HSCT is needed in cases of aplastic <a href="https://docwirenews.com/page/anemia">anemia</a> that are refractory to immunosuppressive therapy or have very low neutrophil counts. They sought to determine the optimal approach when a human leukocyte antigen (HLA)-matched donor is not available and an alternative donor transplantation is required.
The study examined a nationwide registry for patients aged 16 years or older with aplastic anemia who underwent their first HSCT using UCBT or a haploidentical donor plus <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212501s000lbl.pdf" target="_blank" rel="noopener">PTCy</a> between 2016 and 2020. The primary endpoint was overall survival (OS) at one year after HSCT. Secondary endpoints included failure-free survival (FFS), neutrophil and platelet engraftment, and acute and chronic GHVD.
<h2>Haploidentical Donor HSCT Plus PTCy Has Some Advantages Versus UCBT</h2>
A total of 83 patients were analyzed, of which 24 received HSCT from a haploidentical donor plus PTCy and 59 received UCBT. The one-year rate of OS was 78.5% (95% CI, 55.7-90.5) in the haploidentical donor plus PTCy group compared with 77.5% (95% CI, 64.5-86.3; P=.895) in the UCBT group.
The one-year rate of FFS was 78.7% (95% CI, 56.1-90.6) with haploidentical donor plus PTCy versus 62.2% (95% CI, 48.5-73.3; P=.212) with UCBT. Notably, the FFS rate in patients aged under 40 years was significantly higher with haploidentical donor plus PTCy transplants (92.9%; 95% CI, 59.1-99.0) than with UCBT (63.9%; 95% CI, 43.2-78.7; P=.047).
The rates of neutrophil and platelet engraftment were 95.8% (95% CI, 73.9-99.4) and 83.3% (95% CI, 61.5-93.4) in the haploidentical donor plus PTCy group compared with 78.0% (95% CI, 65.1-86.6; P&lt;.001) and 72.9% (95% CI, 59.6-82.4; P=.025) in the UCBT group, respectively. Cumulative incidence rates of grade II to IV acute GHVD and chronic GVHD did not significantly differ between the groups.
Overall, HSCT from a haploidentical donor plus PTCy improved neutrophil and platelet engraftment rates compared with UCBT, as well as FFS rates in patients aged under 40 years, although OS and GVHD outcomes were comparable. Dr. Onishi and colleagues suggested the haploidentical donor plus PTCy method was “promising for alternative donor transplantation in adult patients with aplastic anemia.”
Reference
Onishi Y, Mori T, Yamazaki H, et al. Comparison of haploidentical stem cell transplantation with post-transplantation cyclophosphamide versus umbilical cord blood transplantation in adult patients with aplastic anemia. Transplant Cell Ther. 2023;S2666-6367(23)01548-8. doi:10.1016/j.jtct.2023.09.009
Related: <a href="https://docwirenews.com/post/anemia-inflammation-linked-to-dementia-plus-cognitive-decline">Anemia, Inflammation Linked to Dementia Plus Cognitive Decline</a>

Cecilia Brown

FDA Grants Orphan Drug Designation to 7MW3711 for SCLC

Small Cell Lung Cancer

Anjay Rastogi, MD, PhD

Charlotte Robinson

Latest ZORA Findings Support Efficacy of SZC

ERA Congress 2024

Katy Marshall

FIGHT-202: Analyzing the Effects of Pemigatinib in Patients With Cholangiocarcinoma

Bile Duct Cancer

Latest News

This Transplant Method Shows Promise for Aplastic Anemia in Adults

Anemia

HSCT from a haploidentical donor with PTCy for GVHD prevention improved neutrophil and platelet engraftment compared with UCBT in adult patients with aplastic anemia.

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Career Center

Expert Interviews

Subscribe